Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial

Diabetes Care

Volumn 38, Issue 7, 2015, Pages 1263-1273

  Meier, Juris J ^a   Rosenstock, Julio ^b   Hincelin Méry, Agnès ^c   Roy Duval, Christine ^c   Delfolie, Astrid ^c   Coester, Hans Veit ^d   Menge, Bjoern A ^a   Forst, Thomas ^e   Kapitza, Christoph ^d  

^a ST JOSEF HOSPITAL   (Germany)

^b DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^c SANOFI   (France)

^d Profil   (Germany)

^e Profil Mainz   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; ZP10A PEPTIDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEART RATE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PANCREATITIS; PARALLEL DESIGN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; POSTPRANDIAL STATE;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC EMPTYING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 84942374717     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1984     Document Type: Article

References (50)

1. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care 2013;36(Suppl. 1):S11-S66
2. Inzucchi SE, Bergenstal RM, Buse JB, et al, .; American Diabetes Association (ADA), ; European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
3. Nathan DM, Buse JB, Davidson MB, et al, .; American Diabetes Association, ; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
4. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
5. Riddle MC. Timely initiation of basal insulin. Am J Med 2004;116(Suppl. 3A):3S-9S
6. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006;49:846-854
7. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 2001;24:1734-1738
8. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-269
9. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011;34:2508-2514
10. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 2013;36:2543-2550
11. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE; EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012;35:1225-1231
12. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489-2496
13. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care 2013;36:2497-2503
14. Seino Y, Min KW, Niemoeller E, Takami A; EFC10887 GETGOAL-L Asia Study Investigators. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 2012;14:910-917
15. Buse JB, Rosenstock J, Sesti G, et al, .; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
16. Garber A, Henry R, Ratner R, et al, .; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481
17. Marre M, Shaw J, Brändle M, et al, .; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
18. Nauck M, Frid A, Hermansen K, et al, .; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
19. Russell-Jones D, Vaag A, Schmitz O, et al, .; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-2055
20. Zinman B, Gerich J, Buse JB, et al, .; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230
21. Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Méry A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013;15:642-649
22. Owens DR, Monnier L, Bolli GB. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes Metab 2013;39:485-496
23. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:e001986
24. Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993;104:1640-1647
25. Liotta L, Di Franco A, Pazzagli M, Luconi M. Glycated hemoglobin (HbA1c) measurement in frozen whole blood depends on baseline values of fresh samples. Anal Bioanal Chem 2013;405:429-434
26. Horowitz M, Cook DJ, Collins PJ, Harding PE, Shearman DJ. The application of techniques using radionuclides to the study of gastric emptying. Surg Gynecol Obstet 1982;155:737-744
27. Lorenz M, Pfeiffer C, Steinsträsser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - relationship to postprandial glycemia. Regul Pept 2013;185:1-8
28. Plummer MP, Jones KL, Annink CE, et al. Glucagon-like peptide 1 attenuates the acceleration of gastric emptying induced by hypoglycemia in healthy subjects. Diabetes Care 2014;37:1509-1515
29. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450-459
30. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
31. Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract 2010;16:588-599
32. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728-742
33. Pratley RE, Nauck M, Bailey T, et al, .; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
34. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications 2014;28:399-405
35. U.S. Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee Meeting [Internet], 2014. Available from http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm416154.pdf. Accessed 29 September 2014
36. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010;9:6
37. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114:1788-1803
38. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010;33:1509-1515
39. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-112
40. Leahy JL. Insulin therapy in type 2 diabetes mellitus. Endocrinol Metab Clin North Am 2012;41:119-144
41. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010;103:687-694
42. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab 2011;13:1020-1027
43. Rosenstock J, Rodbard HW, Bain SC, et al, .; Liraglutide-Detemir Study Group. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications 2013;27:492-500
44. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement - executive summary. Endocr Pract 2013;19:536-557
45. Bonafede MM, Kalsekar A, Pawaskar M, et al. Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocr Disord 2011;11:3
46. Farrokhi F, Klindukhova O, Chandra P, et al. Risk factors for inpatient hypoglycemia during subcutaneous insulin therapy in non-critically ill patients with type 2 diabetes. J Diabetes Sci Tech 2012;6:1022-1029
47. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-1029
48. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812
49. Diamant M, Nauck M, Shaginian R, et al. Exenatide BID vs. insulin lispro TIDM added to titrated insulin glargine QD in metformin-treated T2DM patient resulted in similar glycemic control but weight loss and less hypoglycemia: the 4B study [article online], 2013. Available from http://www.abstractsonline.com/plan/viewabstract.aspx?sKey=795037e5-ca6e-44a8-8b54-cfb1400cd733&cKey=f35d109e-da62-4d3c-a9a1-a9dd25395a9f&mkey=%7b89918d6d-3018-4ea9-9d4f-711f98a7ae5d%7d. Accessed 10 November 2013
50. International Diabetes Federation. 2011 guidelines for the management of postmeal glucose in diabetes [article online], 2011. Available from http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf. Accessed 23 October 2014